廣生堂(300436.SZ):乙肝治療創新藥GST-HG141獲得Ib期臨牀試驗倫理委員會批件
格隆匯 4 月 2日丨廣生堂(300436.SZ)公佈,公司於近日獲得吉林大學第一醫院倫理委員會出具的關於乙肝治療創新藥GST-HG141 Ib期臨牀試驗與研究的審查意見,標誌着Ib期臨牀試驗方案已經通過審核確定,試驗已經獲准進入實質性開展期。
GST-HG141 是全新靶點的抗乙肝病毒一類新藥,是乙肝核心蛋白抑制劑,可以抑制HBV(乙肝病毒)衣殼的脱殼與組裝,動物體內藥效試驗展現了優異的病毒抑制作用,已完成的Ia期臨牀試驗顯示整體安全性良好,是公司乙肝臨牀治癒“登峯計劃”重要組成藥物之一。
GST-HG141Ib期臨牀試驗將繼續由病毒性肝炎治療領域著名專家、吉林省肝病研究所所長、吉林大學第一醫院肝膽胰內科主任牛俊奇教授以及吉林大學第一醫院I 期藥物臨牀試驗病房主任丁豔華教授共同擔任臨牀試驗負責人(PI)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.